<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Agents such as 619C89 decrease extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentrations by a primary action at voltage sensitive <z:chebi fb="199" ids="26708">sodium</z:chebi> channels, but <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> also have been shown to decrease extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentration after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To address the question as to whether 619C89's effect upon extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentrations is any different than the effect of the <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="29133">dextrorphan</z:chebi>, 24 rats were given either optimally neuroprotective doses of these drugs or saline prior to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In caudate, the 619C89-treated, but not <z:chebi fb="0" ids="29133">dextrorphan</z:chebi>-treated rats had less microdialysate <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> than ischemic controls </plain></SENT>
<SENT sid="3" pm="."><plain>In cortex, both 619C89- and <z:chebi fb="0" ids="29133">dextrorphan</z:chebi>-treated groups had significantly decreased <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> compared with ischemic controls </plain></SENT>
<SENT sid="4" pm="."><plain>These results support a specific effect of 619C89 upon <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release in caudate but not cortex </plain></SENT>
</text></document>